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Imaging Atherosclerosis
With F18-Fluorodeoxyglucose
Positron Emission Tomography
What Are We Actually Seeing?*
Joseph C. Wu, MD, PHD, Patricia K. Nguyen, MD
Stanford, California
Coronary heart disease remains the leading cause of death in
the U.S. Despite advances in diagnostic imaging and ther-
apy, identification of patients at risk remains challenging.
Anatomical imaging of luminal narrowing and determina-
tion of plaque size alone have proven to be inadequate (1).
In contrast, molecular imaging of plaque composition and
metabolism may not only identify vulnerable patients, but
also enable therapeutic discovery and monitoring (2).
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Over the past 2 decades, it has become clear that
inflammation plays a critical role in plaque destabilization, a
process that is also an obvious target for molecular imaging.
Plaques vulnerable to rupture have a large hypoxic, meta-
bolically active core, containing lipid, oxidized lipid, and
numerous inflammatory cells (primarily foam cells or mac-
rophages). Inflammatory cells secrete proteolytic enzymes
and cytokines, which weaken the thin fibrous cap of these
vulnerable plaques (3). Disruption of fibrous cap allows
thrombotic and inflammatory material in the lesion to
contact blood and form a critical thrombus, occluding
coronary flow and resulting in acute coronary syndrome and
sudden death (4).
Although only largely circumstantial evidence exists so
far, F18-fluorodeoxyglucose (FDG) positron emission to-
mography (PET) imaging has emerged as the most prom-
ising tool for imaging plaque inflammation and vulnerability
(5). Studies in inflammatory diseases have found that
activated inflammatory cells have increased expression of
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relationships to disclose.glucose transporters and FDG uptake (6). Similarly, in
clinical and preclinical studies of atherosclerosis, areas of
high macrophage density correlate with enhanced FDG
uptake in vessels with plaque compared to the contralateral
vessels without plaque (7,8). In addition, FDG uptake is
increased after in vitro stimulation of macrophages with
inflammatory cytokines and growth factors, which are pres-
ent in heightened levels in atheroma (9–11). Finally, statins,
which have anti-inflammatory properties, reduce FDG
signal (12). Together, these data tentatively suggest that
FDG signal in plaque is caused by inflammation.
What Is the Source and Mechanism
of Increased FDG Uptake?
Important questions regarding the source and mechanism of
FDG uptake in the atherosclerotic plaque remain unan-
swered. Are macrophages the only cells capable of taking up
FDG? What is the relative contribution of different cells to
the FDG signal? What causes cells to increase their FDG
uptake (e.g., inflammation or hypoxia or both)? Knowing
the source and mechanism of increased FDG signal will
help us understand the meaning of changes in FDG signal
and its value as a surrogate endpoint.
In this issue of the Journal, Folco et al. (13) help answer
some of these important questions. Using both an in vitro
culture system and ex vivo carotid endarterectomy speci-
mens, they evaluated the effects of hypoxia and inflamma-
tion on FDG uptake in cells specific to atherosclerotic
lesions. They found that both smooth muscle and endothe-
lial cells increased glucose uptake when exposed to inflam-
matory cytokines. Surprisingly, macrophages increased glu-
cose uptake in response to hypoxia but not to inflammatory
cytokines. They further demonstrated that the primary
mechanism for increased glucose uptake was induction of
hexokinase 2, an enzyme that phosphorylates glucose and
enables cell entry. Interestingly, administration of statins
reduced basal as well as hypoxia induced glucose uptake,
suggesting that statins have direct effects on macrophages
independent of their anti-inflammatory effects. These find-
ings challenge the prevailing belief that FDG uptake is a
measure of inflammation.
This paper has several strengths. First, the authors
carefully controlled for confounding factors that might affect
FDG uptake, including glucose concentration and FDG
incubation duration (10). Cells were depleted of endoge-
nous glucose before labeled FDG was added. The FDG
incubation duration was limited to 5 min to ensure linear
uptake of glucose. The short incubation time could explain
why minimal uptake was seen after stimulation with inflam-
matory cytokines. In contrast, after a 30 min FDG incuba-
tion time, a previous study showed that 250% FDG
uptake occurred in monocytes stimulated with IFN com-
pared with controls. Second, the authors carefully regulated
the amount and duration of hypoxia and cytokines, 2 factors
that may affect the degree of cell activation and glucose
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by which hypoxia increased FDG uptake by analyzing the
expression and activity of glucose transporters and hexoki-
nases. Finally, the authors confirmed the viability of inflam-
matory, endothelial, and smooth cells, which ensures cell
death did not confound rates of glucose metabolism.
Shedding Light on Current Controversies
Although the studies described in the preceding text were
performed in vitro, the findings nevertheless may help
resolve current controversies for the application of in vivo
FDG PET imaging in atherosclerosis. The first controversy
is why FDG signal correlates mainly with macrophage
density in studies using endarterectomy specimens and
balloon-injured hypercholesterolemic rabbits even though
endothelial and smooth muscle cells can also metabolize
glucose in vitro (9–11,15). This may occur because macro-
phages are more abundant than these other cell types in
atheroma. In addition, they may preferentially uptake FDG
because these cells appear to respond to both inflammatory
cytokines and hypoxia. The second controversy is why FDG
signal appears to vary with plaque composition. A previous
study has shown that plaques with a predominant lipid
necrotic component and, therefore, a more hypoxic envi-
ronment have higher uptake than those with fibrous or
calcified plaques (16). Interestingly, FDG uptake also co-
localizes with calcifications, which may develop secondary
to chronic hypoxia. Furthermore, FDG uptake correlates
with microvessel density and angiogenesis, both of which
are related to the degree of hypoxia (17). Finally, the
percentage of FDG-positive vascular segments and the
amount of uptake increase with age, which has also been
linked to hypoxia (18). Thus, plaques with varying degrees
of hypoxia may have different amounts of FDG uptake. The
final, and perhaps the most important unresolved issue, is
why results from FDG PET in vivo imaging studies of
atherosclerosis are often inconsistent. For example, al-
though the majority of clinical studies have found that FDG
signal is increased in vessels with plaque compared with the
contralateral vessel, other studies have not found such an
association (19). The presence of FDG has been associated
with age, hypercholesterolemia, and the metabolic syn-
drome, but not with smoking, diabetes mellitus, hyperten-
sion, and obesity. In addition, the extent and intensity of the
FDG signal do not necessarily correlate with cardiovascular
risk factors (19). Because FDG uptake appears to depend on
multiple factors, the inconsistencies found in clinical studies
are not surprising.
Implications for In Vivo FDG PET Imaging
for Atherosclerosis
Taken together, the study by Folco et al. (13) also raises
important questions for in vivo FDG PET imaging for
atherosclerosis. The first question is whether FDG signal
can still be used as a measure of plaque vulnerability.Previous studies have shown that hypoxia exists in
macrophage-dense regions of animal and human atheroscle-
rosis (20). Hypoxia may result from 2 primary causes:
1) limited oxygen supply, which occurs when the intimal
thickness exceeds the maximal oxygen diffusion capacity; or
2) increased demand due to high metabolic activity within
macrophages (21,22). Hypoxia in macrophages has been
shown to increase angiogenesis as well as cytokine produc-
tion, low-density lipoprotein oxidation, and lipid loading in
vitro, all of which contribute to plaque destabilization
(22–24). Hence, it is likely that FDG PET can still evaluate
plaque vulnerability, as both inflammation and hypoxia are
associated with plaque growth and instability.
The second question is whether FDG signal is an
accurate measure of vulnerability. Macrophages activated by
inflammatory cytokines may not be measured if cells do not
have enough time to take up FDG. In addition, FDG has
been shown to underestimate hypoxia compared to more
specific hypoxic markers, based on findings from a previous
oncologic study (25).
The third question that arises from these findings is the
value of FDG signal in monitoring therapy. Although
changes in FDG signal can still be used to monitor therapy,
reduction in FDG signal is not necessarily due to reduction
in inflammation, as shown in this study, where statins
reduced the sensitivity of macrophages to hypoxia but not
because of their anti-inflammatory effects. To use FDG
PET for monitoring, it will be important to differentiate the
effects of a potential drug on decreasing macrophage num-
ber, reaction to hypoxia, and response to inflammatory
cytokines.
Finally, perhaps the most important question is whether
FDG PET is a valuable surrogate endpoint. Findings from
2 prospective studies with 6-month follow-up suggest that
high FDG signal is associated with higher incidence of
clinical events (26,27). The clinical value of FDG PET
imaging will be better elucidated after completion of the
High Risk Plaque Initiative, a prospective event-driven
study involving 6,500 volunteers at risk for cardiovascular
disease (5). It will also be important to perform clinical trials
to determine whether changes in FDG signal after medical
therapy are associated with improvements in morbidity and
mortality.
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